ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0601

Selective Disposition of Voclosporin, Cyclosporine, and Tacrolimus in Renal Tissue

Simon Zhou1, Krishani Kumari Rajanayake2, Miao He2, Bo Wen2, Ankhbayar Lkhagva2, Ernie Yap3, Duxin Sun2, Jennifer Cross1, Kory Engelke1 and Robert B. Huizinga4, 1Aurinia Pharmaceuticals Inc., Rockford, MD, 2University of Michigan, Ann Arbor, MI, 3Aurinia Pharmaceuticals Inc., Edmonton, AB, Canada, 4Reformation Consulting Services, North Saanich, BC, Canada

Meeting: ACR Convergence 2023

Keywords: Mouse, Renal

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 12, 2023

Title: (0582–0608) SLE – Treatment Poster I

Session Type: Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose: The calcineurin inhibitors (CNI) cyclosporine (CSA) and tacrolimus (TAC) were revolutionary when first introduced for solid organ transplant. Voclosporin (VCS), a novel CNI, is the first oral therapy approved for the treatment of active lupus nephritis. Unlike CSA and TAC, VCS has demonstrated consistent pharmacokinetics and pharmacodynamics, eliminating the need for therapeutic drug monitoring. Further, VCS is associated with a more favorable metabolic profile and has not been associated with electrolyte disturbances.

Emerging evidence indicates small molecule therapies display differential disposition within organ tissues. This suggests that CNIs may be differentially distributed and retained in the kidney, potentially explaining differences in their efficacy and safety. Here we assessed in mice and humans the disposition of each CNI in the kidney relative to its systemic drug exposure.

Methods: Single 30 mg/kg doses of CSA, TAC and VCS were administered intravenously (IV) to mice. Following IV administration, kidneys were collected at various time points, flash frozen in liquid nitrogen, and stored at -20 0C. Sections of kidney tissue were mounted on indium tin oxide coated glass slides. Matrix of 10 mg/mL α-Cyano-4-hydroxycinnamic acid in 85% acetonitrile/13% ethanol + 2% water + 0.1% trifluoroacetic acid was sprayed on the tissue, dried for 10 minutes, and subjected to Matrix-assisted Laser Desorption and Ionization Mass Spectrometry Imaging (MALDI-MSI). The systemic and renal clearance (CLr) in humans of CSA and TAC were obtained from literature; pharmacokinetic data on VCS was obtained from data on file. Renal secretion of each drug was compared to its expected passive filtration based on glomerular filtration rate (GFR), fraction unbound in plasma (fu), and respective systemic drug exposure.

Results: MALDI-MSI demonstrated significantly higher concentrations of drug and more diffuse tissue disposition of CSA in mouse kidney compared to VCS (Figure 1). CSA was retained up to 2 hrs post-administration. Higher concentrations and more diffuse disposition of TAC was also noted compared to VCS at 15 and 30 min; TAC was distinctively retained in the cortex and medulla. VCS had moderate distribution in the cortex and was rapidly excreted with low levels present in the kidney after 1 hr.

According to published data, CSA has a measured renal CLr of 1.48 mL/min in humans, representing approximately 10% of expected passive filtration of 12.5 mL/min (Table 1). TAC has a CLr of 0.014 mL/min representing < 2% of expected passive filtration of 1.25 mL/min. VCS has a CLr of 7.82 mL/min representing approximately 200% of its expected passive filtration rate of 3.75 mL/min.

Conclusion: MALDI-MSI revealed differential retention and distribution of CSA, TAC and VCS in mice, consistent with their CLr in humans. Higher drug exposure and >90% renal reabsorption was observed for CSA and TAC, whereas renal handling of VCS suggested significant tubular secretion. The higher rate of secretion and lower overall renal exposure to VCS may be associated with improved safety when compared to the more diffuse distribution and greater renal retention of CSA and TAC.

Supporting image 1

Supporting image 2


Disclosures: S. Zhou: Aurinia Pharmaceuticals Inc., 3, 11; K. Kumari Rajanayake: None; M. He: None; B. Wen: None; A. Lkhagva: Aurinia Pharmaceuticals Inc., 5; E. Yap: Aurinia Pharmaceuticals, 3, 11; D. Sun: Aurinia Pharmaceuticals, 5, 7; J. Cross: Aurinia Pharmaceuticals Inc., 3; K. Engelke: Aurinia Pharmaceuticals, 3; R. Huizinga: Aurinia Pharmaceuticals, 2, 9, 10.

To cite this abstract in AMA style:

Zhou S, Kumari Rajanayake K, He M, Wen B, Lkhagva A, Yap E, Sun D, Cross J, Engelke K, Huizinga R. Selective Disposition of Voclosporin, Cyclosporine, and Tacrolimus in Renal Tissue [abstract]. Arthritis Rheumatol. 2023; 75 (suppl 9). https://acrabstracts.org/abstract/selective-disposition-of-voclosporin-cyclosporine-and-tacrolimus-in-renal-tissue/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2023

ACR Meeting Abstracts - https://acrabstracts.org/abstract/selective-disposition-of-voclosporin-cyclosporine-and-tacrolimus-in-renal-tissue/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology